RT Journal Article
T1 The role of growth hormone and insulin growth factor 1 in the development of non-alcoholic steato-hepatitis: a systematic review
A1 Cristin, Luca
A1 Montini, Amalia
A1 Martinino, Alessandro
A1 Scarano Pereira, Juan Pablo
A1 Giovinazzo, Francesco
A1 Agnes, Salvatore
AB Diabetic and obese patients have a high prevalence of non-alcoholic fatty liver disease (NAFLD). This condition groups a spectrum of conditions varying from simple steatosis to non-alcoholic steatohepatitis (NASH), with or without fibrosis. Multiple factors are involved in the development of NAFLD. However, details about its pathogenesis and factors that promote the progression to NASH are still missing. Growth hormone (GH) and insulin-like growth factor 1 (IGF-1) regulate metabolic, immune, and hepatic stellate cell functions. Increasing evidence suggests they may have roles in the progression from NAFLD to NASH. Following the PRISMA reporting guidelines, we conducted a systematic review to evaluate all clinical and experimental studies published in the literature correlating GH and IGF-1 to inflammation and fibrosis in NAFLD and NASH. Our results showed that GH and IGF-1 have a fundamental role in the pathogenesis of NASH, acting in slightly different ways to produce a synergic effect. Indeed, GH may mediate its protective effect in the pathogenesis of NASH by regulating lipogenesis pathways, while IGF-1 has the same effect by regulating cholesterol transport. Therefore, they could be used as therapeutic strategies in preventing NAFLD progression to NASH.
PB MDPI
YR 2023
FD 2023-02-04
LK https://hdl.handle.net/20.500.14352/104815
UL https://hdl.handle.net/20.500.14352/104815
LA eng
NO Cristin L, Montini A, Martinino A, Scarano Pereira JP, Giovinazzo F, Agnes S. The Role of Growth Hormone and Insulin Growth Factor 1 in the Development of Non-Alcoholic Steato-Hepatitis: A Systematic Review. Cells. 2023;12(4):517
NO 2023 Descuento MDPI
DS Docta Complutense
RD 12 abr 2025